4.17
Diamedica Therapeutics Inc stock is traded at $4.17, with a volume of 89,322.
It is up +5.30% in the last 24 hours and down -15.76% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
See More
Previous Close:
$3.96
Open:
$3.98
24h Volume:
89,322
Relative Volume:
1.04
Market Cap:
$151.71M
Revenue:
-
Net Income/Loss:
$-19.90M
P/E Ratio:
-7.8679
EPS:
-0.53
Net Cash Flow:
$-19.80M
1W Performance:
+17.80%
1M Performance:
-15.76%
6M Performance:
-3.81%
1Y Performance:
+70.20%
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
DMAC
Diamedica Therapeutics Inc
|
4.17 | 151.71M | 0 | -19.90M | -19.80M | -0.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-07-24 | Initiated | H.C. Wainwright | Buy |
Apr-24-24 | Resumed | Craig Hallum | Buy |
Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
Apr-09-21 | Initiated | Oppenheimer | Outperform |
Feb-17-21 | Initiated | ROTH Capital | Buy |
Oct-30-20 | Initiated | Guggenheim | Buy |
Jul-08-20 | Initiated | Maxim Group | Buy |
Apr-30-19 | Initiated | Dougherty & Company | Buy |
Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
LPL Financial LLC Buys 11,500 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Financial Contrast: BioVie (NASDAQ:BIVI) vs. DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve (NASDAQ:DMAC) - Seeking Alpha
Raymond James Financial Inc. Purchases Shares of 15,267 DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
(DMAC) Trading Report - news.stocktradersdaily.com
DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $10.00 - Defense World
Equities Analysts Offer Predictions for DMAC Q1 Earnings - Defense World
DiaMedica Therapeutics Reports 2024 Financial Results - TipRanks
DiaMedica Therapeutics Announces Closing of $8.5 Million Public Offering of Common Shares - Business Wire
H.C. Wainwright lifts DiaMedica stock target to $10 on trial hopes - Investing.com Canada
H.C. Wainwright lifts DiaMedica stock target to $10 on trial hopes By Investing.com - Investing.com South Africa
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2024 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ... - Yahoo
DiaMedica Therapeutics’ Optimistic Earnings Call Highlights - TipRanks
Earnings call transcript: DiaMedica Q4 2024 results and stock surge By Investing.com - Investing.com South Africa
Earnings call transcript: DiaMedica Q4 2024 results and stock surge - Investing.com India
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results - BioSpace
DiaMedica Therapeutics Reports 2024 Financial Results and Strategic Advancements - TipRanks
DiaMedica Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
DIAMEDICA THERAPEUTICS Earnings Results: $DMAC Reports Quarterly Earnings - Nasdaq
Insider Stock Buying Reaches US$9.00m On DiaMedica Therapeutics - Yahoo Finance
Where are the Opportunities in (DMAC) - Stock Traders Daily
DIAMEDICA THERAPEUTICS Earnings Preview: Recent $DMAC Insider Trading, Hedge Fund Activity, and More - Nasdaq
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025 - Business Wire
DiaMedica Therapeutics (DMAC) to Release Quarterly Earnings on Tuesday - Defense World
Insiders At DiaMedica Therapeutics See Good Returns After Buying Stock Worth US$9.00m - Simply Wall St
DiaMedica Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
DiaMedica announces board member Richard Pilnik’s retirement - Investing.com
DiaMedica announces board member Richard Pilnik’s retirement By Investing.com - Investing.com South Africa
Trading (DMAC) With Integrated Risk Controls - Stock Traders Daily
Y Intercept Hong Kong Ltd Takes $81,000 Position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Appoints Daniel J. O’Connor to Board - MSN
DiaMedica welcomes new board member with biopharma leadershi By Investing.com - Investing.com Nigeria
DiaMedica welcomes new board member with biopharma leadershi - Investing.com
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors - Business Wire
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 8.4% in January - MarketBeat
DiaMedica reports on DM199 stroke treatment mechanism By Investing.com - Investing.com Nigeria
DiaMedica reports on DM199 stroke treatment mechanism - Investing.com
DiaMedica Therapeutics Announces Publication Of Dm199'S Mechanism Of Action For The Treatment Of Acute Ischemic Stroke In The Journal Stroke - Marketscreener.com
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke - Business Wire
Learn to Evaluate (DMAC) using the Charts - Stock Traders Daily
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
DiaMedica's Game-Changing Stroke Treatment Takes Center Stage at Major Healthcare Conference (DMAC) - Stock Titan
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 14.5% - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.5%Here's Why - MarketBeat
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):